Mezavant (Mesalazine)

Mesalazine is released in the intestinal lumen where it blocks cyclooxygenase and lipoxygenase enzymes. This inhibition lowers prostaglandin and leukotriene production, decreasing inflammatory cell activity and promoting healing of the colonic mucosa.

The specific dose of Mezavant is determined by the prescribing clinician based on disease severity, patient weight, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for mesalazine in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting Mezavant.

To request Mezavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant (mesalazine) is a first‑line oral 5‑ASA therapy focused on local colonic action, whereas alternatives such as corticosteroids or biologics act systemically or target specific immune pathways. Mesalazine generally has a favorable safety profile but may be less potent in severe disease.

Store Mezavant at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Mezavant is taken orally, usually with water. The tablet or granule should be swallowed whole or, if instructed, mixed with a suitable vehicle such as applesauce, ensuring the full dose is consumed as directed by the prescriber.

Serious risks include severe allergic reactions (anaphylaxis), gastrointestinal bleeding, liver enzyme elevation, pancreatitis, kidney dysfunction, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Mezavant is contraindicated in patients with known hypersensitivity to mesalazine or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in those with a history of severe allergic reactions to 5‑ASA drugs.